EUCTR2008-001259-22-GB进行中（未招募）不适用
A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ART
Merck Serono S.A. Geneva0 个研究点目标入组 200 人开始时间: 2009年1月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •The target population includes subjects with the following attributes:
- •female subject justifying an IVF/ET treatment,
- •between the age of 18 and 35 years (35 not included) at the time of the randomisation visit,
- •an early follicular phase (Day 2-4) serum level of basal FSH <12 IU/L measured in the centre’s own laboratory and taken within 2 months prior to down-regulation start.
- •BMI <30 kg/m2,
- •regular menstrual cycles between 21 and 35 days,
- •have both ovaries present,
- •male partner with semen analysis within the last 6 months prior to the randomisation visit considered adequate as per centre’s standard practice for IVF or intracytoplasmic sperm injection (ICSI). If these criteria are not met, the subject can only be entered if donor sperm will be used,
- •receiving long GnRH agonist protocol – Day 21-22 of preceding cycle until day of hCG.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •To be eligible for inclusion in this trial the subjects must not meet any of the following criteria:
- •1.Had =2 previous ART cycles with a poor response to gonadotrophin stimulation (defined as <5 mature follicles and/or < 3 oocytes collected) or had =2 previous ART cycles with a hyper response (defined as =25 oocytes retrieved),
- •2.Any medical condition, which in the judgement of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug. In case of doubt, the subject in question should be discussed with Merck Serono's Medical responsible,
- •3.Had previous severe OHSS,
- •4.Polycystic ovary syndrome to reduce the risk of the occurrence of OHSS,
- •5.Presence of endometriosis requiring treatment,
- •6.Uterine myoma requiring treatment,
- •7.Any contraindication to being pregnant and/or carrying a pregnancy to term,
- •8.Extra-uterine pregnancy within the last 3 months prior to screening,
- •9.History of 3 or more miscarriages (early or late miscarriages) due to any cause,
- •10.Tumours of the hypothalamus and pituitary gland,
- •11.Ovarian enlargement or cyst of unknown aetiology,
- •12.Ovarian, uterine or mammary cancer,
- •13.A clinically significant systemic disease,
- •14.Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus in the trial subject or her male partner,
- •15.Abnormal gynaecological bleeding of undetermined origin,
- •16.Known allergy or hypersensitivity to human gonadotrophin preparations,
- •17.Any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years prior to the screening visit,
- •18.Entered previously into this trial or simultaneous participation in another clinical trial.
研究者
相似试验
进行中（未招募）
1 期
A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ARTEUCTR2008-001259-22-FRMerck Serono International S.A.
进行中（未招募）
不适用
A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ARTOvarian stimulation in women undergoing assisted reproductive technologyMedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOSEUCTR2008-001259-22-DEMerck Serono S.A.200
进行中（未招募）
不适用
A phase IV prospective, multicentre, randomized, open-label, trial to assess the efficacy and safety of GONAL-f at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL-f 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ARTOvarian stimulation in women undergoing assisted reproductive technologyMedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOSEUCTR2008-001259-22-ITMERCK SERONO INTERNATIONAL SA200
进行中（未招募）
不适用
A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ARTOvarian stimulation in women undergoing assisted reproductive technologyMedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOSEUCTR2008-001259-22-NLMerck Serono International S.A.200
已完成
4 期
A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART)infertilityfertillity problem10013356NL-OMON32275Serono20